Despite the antitumor activity shown by avelumab in patients with advanced pretreated NSCLC patients, this novel anti-PD-L1 compound still has a long pathway to walk in order to demonstrate its potential clinical utility and own personality, for the first and second line scenario in advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.